Much like the rest of the world, pathologists have been watching with fascination as the story of direct-to-consumer testing company Theranos unfolds. From the debut of its revolutionary “Edison machine” technology – purportedly providing instant diagnoses from a single drop of blood – to the discovery that not all was as it seemed, Theranos has been making headlines ever since it first caught the public’s eye in 2013, a decade after its launch. But all that glitters is not diagnostic gold, and in 2015, the Wall Street Journal broke a story announcing that the company’s flagship technology wasn’t being used for most of its tests – and that when it was used, the results might be inaccurate (1).
Since then, the Theranos rollercoaster has been heading steadily downward. Multiple organizations, including the US Food and Drug Administration and the Centers for Medicare and Medicaid Services, found fault with the company’s methods and technologies. Investors and corporate partners separated themselves from Theranos. But now, the saga is officially at an end – at least for company founder Elizabeth Holmes, who has admitted that the proprietary Edison technology doesn’t work, that it was used for only 12 of the more than 200 test types offered to consumers, and that the results from those machines were thrown out. In the wake of this announcement, former partner Walgreens (an American drug retailer) has officially terminated its relationship with Theranos and shut down its on-site testing services (2). Is this the last hurrah for the company? Officially, Theranos remains “fully committed to our mission to provide patients access to affordable health information and look forward to continuing to serve customers… (3)” But with no proprietary technology, no advantages over less expensive providers, and a criminal investigation underway by federal prosecutors and the Securities and Exchange Commission (4), the future looks bleak – not just for Theranos, but for the investors and patients who may have misplaced their trust.
Newsletters
Receive the latest analytical scientist news, personalities, education, and career development – weekly to your inbox.
References
- J Carreyrou, “Hot startup Theranos has struggled with its blood-test technology”, (2015). Available at: http://on.wsj.com/1ZEOHft. Accessed June 13, 2016. M Siconolfi, “Walgreen terminates partnership with blood-testing firm Theranos”, (2016). Available at: http://on.wsj.com/1rksqWY. Accessed June 13, 2016. B Buchanan, “Statement from Theranos” (2016). Available at: http://bit.ly/1ULezTY. Accessed June 13, 2016. R Stross, “Don’t blame Silicon Valley for Theranos”, (2016). Available at: http://nyti.ms/23bGQ8d. Accessed June 13, 2016.
